Dr. Patrick P. Gleason Addresses the Impact of Out-of-Pocket Costs on Adherence and Outcomes

Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.

Related Videos

Related Content

Advertisement

April 29th 2025

Pharmacy Leaders Discuss Innovation and Patient-Centered Care at Asembia’s AXS25 Summit

Pearl Steinzor

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 29th 2025

Trump’s First 100 Days: Workforce Cuts, Drug Pricing, and Medicaid Reform

Pearl Steinzor

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

April 25th 2025

Trump Tariffs on Pharmaceuticals Risk Causing Higher Costs, Drug Shortages

Pearl Steinzor

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Related Content

Advertisement

April 29th 2025

Pharmacy Leaders Discuss Innovation and Patient-Centered Care at Asembia’s AXS25 Summit

Pearl Steinzor

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 29th 2025

Trump’s First 100 Days: Workforce Cuts, Drug Pricing, and Medicaid Reform

Pearl Steinzor

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

April 25th 2025

Trump Tariffs on Pharmaceuticals Risk Causing Higher Costs, Drug Shortages

Pearl Steinzor

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.